Streetbeat News

Regulatory

ATHE

An Independent Data Monitoring Committee has recommended that Alterity Therapeutics' ATH434-201 Phase 2 study in early-stage Multiple System Atrophy should continue as planned. The trial is expected to complete enrollment in Q3 2023, with top-line data expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:58 am

MRK

MRNA

Merck and Moderna have initiated a Phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA for adjuvant treatment of patients with resected high-risk melanoma. The first patients are now enrolling in Australia.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:51 am

AMZN

EWU

Amazon has offered to change its marketplace rules to address concerns raised by the UK's Competition and Markets Authority (CMA). The CMA's preliminary view is that Amazon's offer addresses its competition concerns.

Portfolio Pulse from Charles Gross

July 26, 2023 | 10:09 am

OPT

The American Medical Association's United States Adopted Names Council has approved and adopted the nonproprietary drug name Sozinibercept for Opthea's lead biologic drug candidate, OPT-302.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:06 am

GOOGL

MSFT

NVDA

The S&P 500 and Dow Jones closed higher on Tuesday, with the Dow Jones recording gains for the 12th consecutive session. The Fed is expected to announce a policy decision today, with markets predicting a 25 basis point increase in interest rates. Microsoft Corporation and Alphabet Inc. reported better-than-expected earnings, but Microsoft issued a weak sales outlook for the current quarter. The Nasdaq 100 gained 0.73% on Tuesday, with Microsoft and NVIDIA Corp contributing to the gains. The CBOE Volatility Index fell 0.4% to close at 13.86 on Tuesday.

Portfolio Pulse from Lisa Levin

July 26, 2023 | 9:48 am

FXI

SPY

The US Senate has backed a measure that requires reporting on Chinese technology investments. This move could potentially affect the performance of ETFs like FXI and SPY, which have exposure to Chinese companies.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 8:48 am

BA

LMT

RTN

Senator Bernie Sanders has voiced his opposition to the proposed $886 billion defense bill for fiscal year 2024, calling it a 'corporate welfare program'. He criticized the bill for being more than all other discretionary programs in the federal budget combined. Sanders also highlighted the issues the U.S. faces, including climate change and a broken healthcare system. He named Boeing Co. (BA), Lockheed Martin Corp. (LMT), and RTX Corp. (RTN) among the private contractors who would benefit from the bill.

Portfolio Pulse from Shanthi Rexaline

July 26, 2023 | 8:27 am

KPTI

Karyopharm Therapeutics announced the presentation of updated exploratory subgroup analyses from the SIENDO study of Selinexor for advanced or recurrent TP53 wild-type endometrial cancer at the virtual American Society of Clinical Oncology Plenary Series.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 7:57 am

EWA

Australia's Consumer Price Index (CPI) for Q2 came in at 5.4% YoY, matching estimates but slightly lower than the previous 5.6%. The QoQ CPI was 0.8%, lower than the estimated 1% and the previous 1.4%.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 4:39 am